menu
    • menu
    [{"orgOrder":0,"company":"E-Star Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Modified Atrial Natriuretic Peptide","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"E-Star Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"E-Star Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"E-Star Biotech \/ Not Applicable"},{"orgOrder":0,"company":"E-Star Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Modified Atrial Natriuretic Peptide","moa":"pGC-A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"E-Star Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"E-Star Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"E-Star Biotech \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by E-Star Biotech

    Menu

    E-Star Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            E-Star Biotech

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            E-Star Biotech

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Modified Atrial Natriuretic Peptide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            E-Star Doses First Patient in Phase 2 MANP Trial for Resistant Hypertension

                            Details : MANP (modified atrial natriuretic peptide) pGC-A receptor activator, which increases production of cGMP, ultimately results in vasodilation, being investigated for hypertension.

                            Product Name : MANP

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            February 05, 2025

                            Lead Product(s) : Modified Atrial Natriuretic Peptide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            E-Star Biotech

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            E-Star Biotech

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Modified Atrial Natriuretic Peptide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            E-Star BioTech to Start MANP Phase 2 Trial in Resistant Hypertension

                            Details : The Company's lead asset, MANP, is currently being investigated in a Phase 2 clinical trial studies for the treatment of hypertension.

                            Product Name : MANP

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            October 08, 2024

                            Lead Product(s) : Modified Atrial Natriuretic Peptide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth